Skip to main menu | Skip to main content
Canada FlagUnited States | Apotex Worldwide
For media inquiries, please contact us here

   Email

News

Sep 5, 2023
Apotex Corp. Launches Brimonidine Tartrate Ophthalmic Solution, 0.1% in the United States

Apotex Corp. Launches Brimonidine Tartrate Ophthalmic Solution, 0.1% in the United States

Brimonidine Tartrate Ophthalmic Solution 0.1%Weston, Florida (September 5, 2023) – Apotex Corp. has released its latest ophthalmic product in the United States, announcing today that brimonidine tartrate ophthalmic solution, 0.1% is now available.

Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

“Open-angle glaucoma impacts over 2.7 million Americans, and millions more have ocular hypertension. Bringing this product to market will make a real difference for these patients, who depend on this medicine to preserve their vision,” says Peter Hardwick, President, Apotex Corp.

“We’re excited to be able to offer this high-quality, cost-saving option to prescribers and patients across the country.”

Prescribing information can be found at https://www.apotex.com/products/us/downloads/pre/brim_opso_0.1_ins.pdf.

About Apotex Corp.

Apotex Corp. is a US based company, headquartered in Weston, Florida. It and its global affiliates are leaders in generic pharmaceuticals and biosimilars and are committed to supplying patients with a broad portfolio of high-quality, affordable medicines covering all major therapeutic areas.

-30-

All media enquiries :
Jordan Berman
Vice-President, Global Corporate Affairs
Apotex Inc.
jberman@apotex.com
Mobile: 647-272-2287